Zobrazeno 1 - 4
of 4
pro vyhledávání: '"EFTHALIA LALLA"'
Autor:
Nikolaos Tsoulos, Konstantinos Agiannitopoulos, Georgia Pepe, Eirini Papadopoulou, Georgios N Tsaousis, Despina Apostolopoulou, Angeliki Meintani, Vassileios Venizelos, Christos Markopoulos, Rodoniki Iosifidou, Sofia Karageorgopoulou, Christos Christodoulou, Ioannis Natsiopoulos, Konstantinos Papazisis, Maria Vasilaki-Antonatou, Eleftherios Kabletsas, Amanta Psyrri, Stylianos Giassas, Dimitrios Ziogas, Efthalia Lalla, Anna Koumarianou, Christos Papadimitriou, Vahit Ozmen, Sualp Tansan, Kerim Kaban, Tahsin Ozatlı, Dan Tudor Eniu, Angelica Chiorean, Alexandru Blidaru, George Nasioulas
Publikováno v:
Cancer Research. 82:P2-09
Background: Breast cancer is the most frequently diagnosed cancer in women and about 10% of breast cancer cases are hereditary. BRCA1 and BRCA2 are the genes most frequently associated with Hereditary Breast Cancer, although there are numerous other
Autor:
Dimitrios Bafaloukos Snr, Athina Christopoulou, Anastasios Boutis, Gerasimos Aravantinos, Georgia-Angeliki Koliou, Sofia Lampaki, Helena Linardou, George Fountzilas, Panagiotis Papantoniou, Efthalia Lalla, Eleni Res, Nicoleta Pastelli, Margarita-Ioanna Koufaki, Georgios Rigakos, Pavlos Papakotoulas, Giannis Mountzios, Dionisios Spyratos, Anna Koumarianou, Anastasios Grivas, Athanassios Vozikis, Georgios Oikonomopoulos, Ioannis Kontogiorgos
Publikováno v:
Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy, Vol Volume 12, Pp 93-102 (2021)
Lung Cancer: Targets and Therapy, Vol Volume 12, Pp 93-102 (2021)
Giannis Mountzios,1 Sofia Lampaki,2 Georgia-Angeliki Koliou,3 Athanassios Vozikis,4 Ioannis Kontogiorgos,4 Panagiotis Papantoniou,4 Margarita-Ioanna Koufaki,4 Eleni Res,5 Anastasios Boutis,6 Athina Christopoulou,7 Nicoleta Pastelli,8 Anastasios Griva
Autor:
GEORGE DOUGANIOTIS, GEORGE KESISIS, EFTHALIA LALLA, IPPOKRATIS KORANTZIS, IOANNIS BOUKOVINAS, KONSTANTINOS PAPAZISIS
Publikováno v:
Cancer Diagn Progn
Background/Aim: Low expression of HER2 has defined a new “HER2-low” subgroup of breast cancer with distinct clinicopathological characteristics and both prognostic and predictive implications. The impact of low HER2 expression in metastatic hormo
Autor:
Helena Linardou, Efthalia Lalla, Georgios Koumakis, Georgia-Angeliki Koliou, Sofia Karteri, Evangelia Razis, Davide Mauri, George Fountzilas, Sofia Karageorgopoulou, Anna Koumarianou, Eleni Res, Gerasimos Aravantinos, Athina Christopoulou, Ioannis Boukovinas, Vassiliki Rapti, D. Tryfonopoulos, Evangelia Moirogiorgou, Amanda Psyrri, Athanassios Vozikis, Dimitrios Bafaloukos, Zacharenia Saridaki, Elena Fountzilas, Adamantia Nikolaidi, I. Binas, Giannis Mountzios, Anastasios Boutis, Ioannis Kontogiorgos, Flora Zagouri, Cleopatra Rapti, Achilleas Nikolakopoulos
Publikováno v:
ESMO Open
Background We evaluated real-world clinical outcomes and toxicity data and assessed treatment-related costs in patients with advanced breast cancer who received treatment with cyclin-dependent kinase inhibitors (CDKi). Patients and methods We conduct